BIOMARIN PHARMACEUTICAL INC (BMRN) — SEC Financial Statements & Analysis

BIOMARIN PHARMACEUTICAL INC (BMRN) is a pharmaceutical preparations company, incorporated in DE. BIOMARIN PHARMACEUTICAL INC trades on Nasdaq as: BMRN. BIOMARIN PHARMACEUTICAL INC (BMRN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, BIOMARIN PHARMACEUTICAL INC carries a market cap of $11.07B, a P/E ratio of 151.67x, a P/B ratio of 1.75x, a P/S ratio of 3.25x, an enterprise value of $14.38B, and an EV/EBITDA multiple of 47.58x. On profitability, it posts a gross margin of 76.12%, an operating margin of 4.38%, a net margin of 2.14%, a Return on Equity (ROE) of 1.18%, a Return on Assets (ROA) of 0.76%, and a Return on Invested Capital (ROIC) of 0.96%. Per share, it reports EPS of $0.38, diluted EPS of $0.38, free cash flow per share of $3.82, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 11.20% year-over-year, net income growth of -88.90% year-over-year, and EPS growth of -88.98% year-over-year. On the balance sheet, it maintains a current ratio of 2.39x, a quick ratio of 1.32x, working capital of $2.31B, a debt-to-equity ratio of 0.85x, a debt ratio of 0.46, an interest coverage ratio of 1.79x, free cash flow of $738.18M (TTM), and net debt of $3.31B. Figures sourced from SEC EDGAR.

Market Cap

$11.07B

P/E TTM

151.67x

EPS TTM

$0.38

P/B TTM

1.75x

ROE TTM

1.18%

ROA TTM

0.76%

Debt To Equity

0.85x

Free Cash Flow TTM

$738.18M

Net Revenue TTM Growth 1Y

11.20%

Data as of 2026-06-30 · Source: SEC EDGAR